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Inflammation participates in tissue repair through multi-
ple mechanisms including directly regulating the cell fate
of resident progenitor cells critical for successful regenera-
tion. Upon surveying target cell types of the TNF ligand
TWEAK, we observed that TWEAK binds to all progenitor
cells of the mesenchymal lineage and induces NF-jB
activation and the expression of pro-survival, pro-prolif-
erative and homing receptor genes in the mesenchymal
stem cells, suggesting that this pro-inflammatory cytokine
may play an important role in controlling progenitor cell
biology. We explored this potential using both the estab-
lished C2C12 cell line and primary mouse muscle myo-
blasts, and demonstrated that TWEAK promoted their
proliferation and inhibited their terminal differentiation.
By generating mice deficient in the TWEAK receptor Fn14,
we further showed that Fn14-deficient primary myoblasts
displayed significantly reduced proliferative capacity and
altered myotube formation. Following cardiotoxin injec-
tion, a known trigger for satellite cell-driven skeletal
muscle regeneration, Fn14-deficient mice exhibited re-
duced inflammatory response and delayed muscle fiber
regeneration compared with wild-type mice. These results
indicate that the TWEAK/Fn14 pathway is a novel regu-
lator of skeletal muscle precursor cells and illustrate an
important mechanism by which inflammatory cytokines
influence tissue regeneration and repair. Coupled with our
recent demonstration that TWEAK potentiates liver pro-
genitor cell proliferation, the expression of Fn14 on all
mesenchymal lineage progenitor cells supports a broad
involvement of this pathway in other tissue injury and
disease settings.
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Introduction
Inflammation is the first-line defensive mechanism to noxious
insults ranging from microbial infections to physical injury
(Nathan, 2002). Although excessive inflammation can have
devastating consequences, in most cases inflammatory
responses lead to effective clearance of pathogens and/or
healing. In fact, depletion of inflammatory cell types such
as macrophages has been shown to result in delayed repair
response in injury models of a number of tissues, including
muscle (Lescaudron et al, 1999), mesothelium (Mutsaers et al,
2002), and both the central (Kotter et al, 2001) and peripheral
nerve systems (Luk et al, 2003). It is now well established that
inflammation contributes to tissue repair by clearing debris,
engulfment and digestion of apoptotic/necrotic cell bodies,
epithelial closure and promoting angiogenesis (Nathan, 2002).
Much underappreciated until recently, the various cytokines
secreted by inflammatory cells also directly influence the
properties of progenitor cells that reside in tissues undergoing
repair and regeneration (Duffield, 2003). For example, the
macrophage-derived cytokine TNF promotes the proliferation
of oligodendrocyte progenitors after cuprizone-induced de-
myelination (Arnett et al, 2001). Similarly, soluble factor(s)
secreted by macrophages can also drive the proliferation of
mesothelial cells (Mutsaers et al, 2002) and muscle satellite
cells (Merly et al, 1999) during mesothelial and muscle regen-
eration, respectively. However, it has also been demonstrated
that inflammatory cytokines block neural progenitor differen-
tiation (Ekdahl et al, 2003; Monje et al, 2003), suggesting that
the biological consequence of these inflammatory mediators
on tissue repair and regeneration is likely a complex one.
The largely macrophage-derived cytokine TWEAK and its
receptor Fn14 are relatively new additions to the TNF super-
family, which includes well-known modulators of cell pro-
liferation, differentiation and apoptosis (Locksley et al, 2001).
Originally identified as a weak inducer of cell death in tumor
cell lines (Chicheportiche et al, 1997), TWEAK was subse-
quently shown to exert pleiotropic effects on a variety of cell
types in vitro, including pro-angiogenic activities on endothe-
lial cells (Lynch et al, 1999; Jakubowski et al, 2002) and pro-
inflammatory activities on epithelial cells (Chicheportiche
et al, 1997), astrocytes (Saas et al, 2000), dermal fibroblasts
and synoviocytes (Chicheportiche et al, 2002). Conspicuously
absent from the TWEAK-responding cell types are lymphocytes,
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and Fn14 expression on these cells has not been demonstrated.
Interestingly, the TWEAK receptor Fn14 is an FGF-inducible
gene and is highly upregulated in liver injury and regeneration
and arterial wounding (Feng et al, 2000; Wiley et al, 2001),
suggesting a regulatory role in settings of tissue injury and
repair. Recently, we demonstrated that the TWEAK/Fn14 path-
way is a potent inducer of liver progenitor cell proliferation in
response to chemical injury in vivo (Jakubowski et al, 2005).
However, the physiological relevance of the TWEAK/Fn14
pathway in other contexts remains elusive.
In this study, we explored the potential role of TWEAK/
Fn14 pathway in modulating mesenchymal progenitor cell
biology in vitro and in vivo in a model of skeletal muscle
injury and repair. We showed that all progenitor cells of
mesenchymal lineage express the TWEAK receptor Fn14.
We further demonstrated that TWEAK promotes proliferation
of both an established myoblast cell line and primary muscle
myoblasts. Finally, by generating mice deficient in Fn14, we
established that the TWEAK/Fn14 pathway is required for
optimal muscle regeneration in vivo.
Results
Mesenchymal progenitor cells are a novel target cell
type of TWEAK
In our effort to identify in vivo target cell types for TWEAK,
we found that TWEAK binds to progenitor cells of the
mesenchymal lineage, including human primary mesenchy-
mal stem cells, skeletal muscle myoblasts and preadipocytes
as well as chondrocyte and osteoblast precursors cultured
in vitro (Figure 1A). We also demonstrated that the TWEAK
receptor Fn14 was expressed on these progenitor cells by
staining with the anti-human Fn14 monoclonal antibody
ITEM-4 (Figure 1A). To see if these cells would respond to
TWEAK, we examined NF-kB activation in mesenchymal
stem cells and osteoblast precursors upon TWEAK treatment
as it has previously been shown that Fn14 signal transduction
is mediated through the TRAF-binding site in its cytoplasmic
tail (Brown et al, 2003). As shown in Figure 1B, TWEAK
induced robust NF-kB activation in both cell types as mea-
sured by the amount of activated p65 present in the cell lysate
following TWEAK stimulation using the TranAM assay
system, indicating that progenitor cells of the mesenchymal
lineage are indeed TWEAK-responsive cells. The ability of
TWEAK to induce NF-kB activation in these progenitor
cells is further confirmed by transcription profiling study of
mesenchymal stem cells treated with TWEAK. Even in the
high serum culture condition (10% FBS), TWEAK induced
robust transcriptional upregulation of well-known NF-kB-
regulated genes, including TRAF1 and 3, NF-kB2 and RelB,
which are regulators of NF-kB pathway themselves, and
pro-survival genes such as A20 and c-IAP2, as well as cell
adhesion genes such as ICAM-1 and VCAM-1n (Figure 1C).
Importantly, under low (0.2%) or medium (2%) serum
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Figure 1 Human mesenchymal progenitor cells are a novel target cell type for TWEAK. (A) Human primary mesenchymal stem cells, skeletal
muscle myoblasts, preadipocytes, chondrocytes and osteoblast precursors (Cambrex) were cultured according to the manufacturer’s protocols.
First-passage cells showed staining for TWEAK binding using Fc-TWEAK and for expression of Fn14 using the anti-hFn14 mAb ITEM-4. Anti-
mouse and anti-human Fcs were used as negative controls, (B) NF-kB was activated in human mesenchymal stem cells (hMSCs) and osteoblast
precursors (hOsteos) following 2 or 6 h of treatment with 100 ng/m TWEAK (Tw). Activation was measured using the TransAM NF-kB p65
activation assay system with cell lysates from normal and TNF-treated HeLa cells serving as negative and positive controls. The assays were
carried out in triplicate and the data shown are representative of three independent experiments. (C) List of representative genes induced by
TWEAK (100 ng/ml versus heat-inactivated TWEAK 100 ng/ml) in mesenchymal stem cells in low serum (LS: 0.2% FBS), moderate serum (MS:
2% FBS) and high serum (HS: 10% FBS). (D) List of some cell cycle-related genes induced by TWEAK (versus inactivated TWEAK) in
mesenchymal stem cells cultured under low-serum conditions (0.2% FBS). Triplicate samples were analyzed for each condition and the fold
changes were calculated using averages from triplicates. All fold changes reached statistical significance (Po0.01).
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conditions, TWEAK also induced the expression of many
cell cycle-related genes including cdc2, cyclin A2, survivin,
MAD2, among others (Figure 1D and data not shown). These
results therefore indicate that TWEAK may regulate cell fate
decisions of progenitor cells.
TWEAK promotes proliferation and inhibits terminal
myogenesis of C2C12 cells
To further investigate how TWEAK might influence cell fate
of progenitor cells, we took advantage of the well-established
in vitro cell differentiation model of the mesenchymal
lineage, C2C12 terminal myogenesis. We first confirmed
that, similar to human skeletal muscle myoblasts, the murine
C2C12 myoblasts also expressed Fn14 on their surface
(Figure 2A and B). As expected, upon switching from regular
growth medium (GM) (containing 15% FBS) to (DM), (con-
taining 2% horse serum), mononuclear proliferating C2C12
cells enter into a well-characterized differentiation program
that includes cell cycle arrest, fusion of mononuclear cells
and formation of multinucleate myotubes (Figure 2C). In the
presence of TWEAK, however, C2C12 cells largely remained
as a monolayer of mononuclear cells even when placed in
DM (Figure 2D). Both the anti-TWEAK blocking antibody
ABG.11 and the hFn14-hFc-soluble TWEAK receptor effec-
tively reversed the inhibition of myotube formation, confirm-
ing the specificity of our observation (Figure 2E and not
shown). Importantly, addition of the anti-Fn14 blocking anti-
body P2D3 also was able to reverse the inhibitory effect
of TWEAK (Figure 2F), demonstrating that the activity of
TWEAK on C2C12 cells was mediated through the Fn14
receptor. As it is well documented that TNF is a potent
inhibitor of myogenesis in vitro (Szalay et al, 1997; Miller
et al, 1988), we decided to investigate if there was any
potential crosstalk between the TNF and TWEAK pathways
in the C2C12 myogenesis model. Although the soluble TNF
receptor mTNFRI-Fc totally reversed the inhibition of C2C12
differentiation by TNF (Figure 2G and H), it had no effect on
the inhibitory activity of TWEAK (Figure 2I). A similar result
was also seen using anti-TNF or anti-TNFRI blocking anti-
bodies (data not shown). Conversely, the anti-TWEAK block-
ing antibody ABG.11 and anti-Fn14 blocking antibody P2D3
both failed to block TNF’s ability to inhibit C2C12 myo-
genesis (Figure 2J and not shown). Based on these obser-
vations, we concluded that although both TWEAK and TNF
exhibit similar potent inhibitory effects on C2C12 differentia-
tion, these two act independently of each other through
different receptors.
Terminal myogenic differentiation of C2C12 cells requires
exit from the cell cycle and expression of myogenic transcrip-
tion factors such as myogenin, which in turn activate the
transcription of an array of muscle-specific genes. To under-
stand the molecular events underlying TWEAK’s inhibitory
effect on C2C12 myogenesis, we performed profiling studies
comparing global gene expression patterns of C2C12 cells
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Figure 2 The TWEAK receptor Fn14 is expressed by myoblasts, and TWEAK inhibits differentiation of C2C12 cells. (A) FACS showed that most
human skeletal muscle myoblasts (HSMM, from Cambrex) expressed Fn14, as well as the lineage marker CD56, on the cell surface.
(B) Myoblasts of the mouse C2C12 line also expressed Fn14 on the surface. (C–J) Myotube formation by C2C12 cells in low-serum
differentiation medium (DM) was assessed after addition of the following reagents: (C) no addition, myotube formation was extensive,
(D) 100 ng/ml murine recombinant TWEAK, myotube formation inhibited; (E) 100 ng/ml mTWEAKþ 10mg/ml anti-TWEAK mAb ABG.11,
normal myotubes; (F) 100ng/ml mTWEAKþ 10mg/ml anti-Fn14 mAb P2D3, normal myotubes; (G) 5 ng/ml mTNF; decreased myotubes;
(H) 5 ng/ml mTNFþ 10mg/ml mTNFRI-Fc, normal myotubes; (I) 5 ng/ml mTWEAKþ 10 mg/ml mTNFRI-Fc to block TNFR1, decreased
myotubes; and (J) 5 ng/ml mTNFþ 10 mg/ml anti-TWEAK ABG.11, decreased myotubes. Phase contrast at 5 days after switching to DM with
indicated additions; images are representative of at least 10 independent experiments.
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cultured in low-serum DM with or without TWEAK, and a
number of representative genes with significant alteration in
their expression levels are listed in Figure 3A. Upon analysis,
we noticed that the expression levels of a large number of
genes involved in cell cycle progression (i.e., cyclin D1 and
c-myc), DNA/RNA synthesis (i.e., DNA polymerase A and
TFIIIA) as well as chromosome remodeling (i.e., chromatin
assembly factor) were dramatically increased with TWEAK
stimulation, suggesting that these cells were mitotically
active (Figure 3A). Using BrdU labeling, we confirmed that
most C2C12 cells in DM in the absence of TWEAK are
nonmitotic as expected. However, TWEAK-treated C2C12
cells were almost all BrdU positive, indicating that TWEAK
stimulation potently promoted proliferation of these C2C12
cells even under low-serum condition (Figure 3B). Given that
withdrawal from cell cycle is a well-established prerequisite
for C2C12 terminal differentiation (Walsh and Perlman,
1997), it is likely that the perturbation of cell cycle arrest
in these cells by TWEAK is responsible for the blockade in
C2C12 myogenesis. The failure in myogenic progression in
the presence of TWEAK was reflected at the molecular level
by the decreased expression, based on both DNA array and
Western blot analyses (Figure 3A and C), of the muscle-
specific transcription factors myogenin and MyoD, which
are critical for the terminal differentiation of C2C12 cells
and govern the expression of many muscle-specific genes.
Consequently, the overall expression levels of multiple
muscle-related genes, such as the muscle structural proteins
myosin heavy and light chains, as well as the muscle meta-
bolic gene carbonic anhydrase, were significantly suppressed
by TWEAK treatment (Figure 3A). This suppression of mus-
cle-specific gene expression by TWEAK was accompanied by
drastic phenotype differences between the TWEAK-treated
and untreated cells. Whereas the majority of TWEAK-treated
C2C12 cells maintained the undifferentiated mononuclear
morphology with few actin filaments even in low-serum
DM, the untreated C2C12 cells fully differentiated and
became fused multinucleated myotubes, as revealed by
DAPI and phalloidin staining (Figure 3D).
Generation of Fn14-deficient mice
The profound effect of TWEAK on the established myoblast
line C2C12 suggested that the TWEAK/Fn14 pathway may
indeed be an important pathway regulating progenitor cell
biology. To better understand the physiological relevance of
this pathway, we decided to generate mice deficient in the
TWEAK receptor Fn14. Using the standard gene-targeting
strategy, anB10-kb Kpn1 genomic DNA fragment containing
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Figure 3 TWEAK blocks the myogenic program and prevents cell cycle arrest in C2C12 cells. (A) TWEAK induced expression level changes in
many genes important for cell cycle control and myogenic differentiation,for example, the muscle-specific transcription factors myogenin and
MyoD. Fold changes and s.d.s were calculated using data from duplicate samples that passed statistical tests. (B) C2C12 cells continued to
proliferate in low-serum DM when treated with TWEAK as shown by the much larger percentage of cells that incorporated BrdU in TWEAK-
treated than in untreated cultures. Cells were analyzed after culture in DM for 3 days with or without 100 ng/ml of Fc-TWEAK and after 12 h
BrdU labeling. (C) Myogenin protein was much lower after TWEAK treatment as shown by immunoblots of C2C12 cells in DM in the absence
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the entire mouse Fn14 gene was isolated and a targeting
vector was designed to delete the first two exons (encoding
amino acids 1–66), which contain the entire extracellular
ligand-binding domain of Fn14 (Supplementary Figure S1a).
Embryonic stem cell clones undergoing successful homo-
logous recombination (8 out of 136) were identified by both
genomic Southern blot and PCR analysis (Supplementary
Figure S1a and data not shown) and injected into the
C57BL/6 blastocysts to generate chimeras. Homozygous
Fn14 null mice were obtained through standard breeding
schemes (see Materials and methods). Homozygous
Fn14/ mice appear normal and do not have any obvious
developmental defect in muscle or other tissues (Supple-
mentary Figure S1e and unpublished data). To confirm the
presence of a null mutation, we derived wild-type, hetero-
zygous and homozygous mouse embryonic fibroblast (MEF)
clones and assayed for both Fn14 mRNA and protein surface
expression. As shown in Supplementary Figure S1b and c,
both Northern blot and RT–PCR analysis clearly indicated
the lack of Fn14 mRNA in Fn14/ MEF clones. Importantly,
FACS staining also demonstrated that TWEAK no longer
bound to individually derived Fn14/ clones (Supple-
mentary Figure S1d), confirming the lack of Fn14 on the
surface of these cells and that Fn14 is the only receptor
for TWEAK. The residual low-frequency binding detected
by Fc-TWEAK in Fn14/ (also seen in Fn14þ /þ ) MEF
clones appears to be nonspecific, as we could not compete
it off using the soluble receptor Fn14-Fc (not shown).
TWEAK/Fn14 pathway regulates the proliferative
potential of primary mouse muscle myoblasts
Our in vitro C2C12 results strongly suggested that the
TWEAK/Fn14 pathway might also regulate the properties of
primary myogenic precursor cells such as muscle satellite
cells and their committed myoblast progeny. Following con-
firmation that more than 95% of cells in our primary myo-
blasts preparation do indeed express Fn14 on the surface (not
shown), we examined the direct effect of TWEAK on the
growth and differentiation characteristics of mouse primary
myoblasts isolated from the limb muscles of 6 to 8-week-old
mice. In GM, addition of TWEAK resulted in an enhanced
proliferation of the primary myoblasts as reflected by the
presence after 3 days of growth of B2 more mononuclear
myoblasts in TWEAK-treated than in untreated cultures
(Figure 4A and B). The proliferative effect of TWEAK was
specific because the proliferation rate returned to basal level
upon treatment with the TWEAK-neutralizing reagents anti-
TWEAK antibody or Fn14-Fc (Figure 4C and not shown).
Inclusion of TWEAK in the DM of primary myoblasts, on the
other hand, resulted in significantly reduced myotube forma-
tion and the appearance of dying cells (Figure 4D and E). This
cell death response of primary myoblasts was quite different
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cultures of primary myoblasts treated with 100 ng/ml Fc-TWEAK (B) containedB2 more cells than untreated cultures (A) or cultures treated
with both Fc-TWEAK and Fn14-Fc to block receptor function (C). (D, E) After 4 days in low-serum differentiation medium, untreated cultures
of primary myoblasts formed multinucleate myotubes (D), whereas myotubes were rarely found in TWEAK-treated cultures (E). (F) Primary
myoblasts isolated from Fn14-deficient mice produced fewer progeny than wild-type myoblasts in culture. Results from two independent
experiments (exp. no. 1 and exp. no. 2) are shown. In each experiment, myoblasts were obtained from two individual wild-type (WT) and two
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from the response of C2C12 myoblasts, which remained alive
and capable of proliferation in the TWEAK-containing DM
for at least a week. Although we do not yet understand the
precise reason(s) for the different responses of C2C12 and
primary muscle cells, it is known that immortalized myo-
genic cell lines have mutations in cell cycle regulatory genes
(Nowak et al, 2004); so it is not surprising that primary cells
would behave differently than an established cell line in both
proliferative potential and susceptibility to apoptosis.
Primary myoblasts isolated from Fn14-deficient mice pro-
duced fewer viable progeny in culture than did myoblasts
from wild-type mice (Figure 4F). To rule out the possibility
that the proliferation of wild-type myoblasts was ‘artificially’
enhanced by exogenous TWEAK from the chicken extracts
used in the culture media or TWEAK produced by myoblasts
in an autocrine manner, we included the soluble Fn14-Fc
decoy receptor in the wild-type myoblasts culture and
observed no reduction in the number of progeny (data not
shown). Based on these results, we conclude that the
TWEAK/Fn14 pathway is intrinsically required for the full
proliferative potential of mouse myoblasts. Interestingly,
while Fn14-deficient myoblasts retained the ability to differ-
entiate into myotubes when cultured in low-serum DM, we
have consistently noticed morphological differences in myo-
tubes fused from wild-type versus Fn14/ myoblasts in that
the Fn14/myoblasts seemed to form thicker myotubes
upon fusion (Figure 4G and H). The underlying molecular
basis for this difference is not yet known.
TWEAK/Fn14 pathway participates in muscle
regeneration in vivo
Muscle satellite cells are adult muscle precursor cells residing
quiescently under the basal lamina of the muscle fiber.
Although not required for early muscle development, these
cells are believed to be the main, if not the only, contributor
to muscle regeneration in response to damage or increase in
workload. Upon activation, satellite cells are capable of
proliferating to produce committed myoblasts as progeny,
which then repair injured muscle either by fusing with
injured pre-existing myofibers or by forming entirely new
myofibers (Hawke and Garry, 2001). Although histologically
well characterized, the stepwise program of muscle regenera-
tion is incompletely understood at the molecular level and
a limited number of regulating factors have been identified
to date (Morgan and Partridge, 2003). Based on our culture
results, we hypothesized that the TWEAK/Fn14 pathway
might be a novel regulator of muscle regeneration in vivo,
and we tested this idea by comparing regeneration of wild-
type versus Fn14/ muscle in vivo following injury induced
by the snake venom cardiotoxin (Couteaux et al, 1988).
We first examined the expression patterns of TWEAK and
Fn14 mRNAs following cardiotoxin injection in the tibialis
anterior (TA) muscle of wild-type and Fn14/ mice using
in situ hybrization analysis. The levels of both TWEAK and
Fn14 were minimal in the undamaged wild-type muscle
tissue (Figure 5A and G, quantified in Figure 5M), and
TWEAK mRNA expression was also low in undamaged
Fn14/ muscle (Figure 5B). As expected, Fn14 mRNA was
essentially undetectable in FN14/ muscles (Figure 5H, J, L
and M).
Three days after cardiotoxin injury, expression levels of
both TWEAK and Fn14 were significantly increased in the
damaged areas of wild-type muscles (Figure 5C, I and M) and
TWEAK mRNA to approximatly the same level in Fn14/ as
in wild-type muscles (Figure 5D and M). The similar increase
in TWEAK mRNA in wild-type and Fn14/ muscles at 3
days after cardiotoxin treatment was confirmed by quantita-
tive PCR (not shown). By day 5, TWEAK expression had
subsided considerably in wild-type muscles, whereas the
level of Fn14 remained as high at day 5 as at day 3 (Figure
5E, K and M). The finding that increased TWEAK expression
persisted for a longer period of time in injured muscles of
Fn14 / mice than in wild-type mice (Figure 5E versus F)
suggests that inactivation of the TWEAK receptor altered the
injury response to cardiotoxin in the Fn14-deficient mice.
Two lines of evidence suggested that macrophages were
the major source of the increased TWEAK expression in
injured wild-type and Fn14/ muscles. First, bright-field
analysis revealed a clear association of TWEAK expression
with infiltrating inflammatory cells, whereas Fn14 expression
seemed to adopt a much more diffuse pattern (data not
shown). Second, using a quantitative PCR assay, we found
that macrophages (i.e., Mac-1-positive cells) isolated from
both wild-type and Fn14/ TA muscles at 3 days after
cardiotoxin injection expressed relatively large amounts of
TWEAK mRNA (Figure 5N). In contrast, very little TWEAK
mRNA was found in either the non-macrophage cell fraction
(i.e., Mac-1-negative cells) or in myogenic cells purified by
Percoll gradient fractionation (Figure 5N).
To begin to determine if signaling by additional members
of the TNF superfamily might also be altered in FN14-
deficient compared with wild-type mice, we carried out
quantitative PCR measurements to measure in regenerating
TA muscles (n¼ 3) the relative levels of the mRNAs encoding
two TNF family ligands, TNFa and EDA (ectodysplasin), and
their respective receptors (TNFR1, TNFR2, and XEDAR), as
these two TNF ligand/receptor pathways have previously
been suggested to play a role in muscle regeneration
(Guttridge et al, 2000; Newton et al, 2004). As shown in
Figure 5O, we indeed found that the levels of these mRNAs
were significantly induced following cardiotoxin-induced in-
jury, but did not differ significantly between the wild-type
and Fn14-deficient muscles at 3 days, although there seems
to be a trend of increased expression in the Fn14 knockout
mice, suggestive of potential compensatory mechanism
(see Discussion).
Defective inflammatory response and muscle
regeneration in Fn14/ mice following cardiotoxin-
induced muscle injury
We next assessed muscle regeneration in response to cardio-
toxin injury in both wild-type and Fn14 knockout mice using
histological analysis. Similar to previous reports, cardiotoxin
injection in the TA muscles caused considerable damage
to muscle fibers, triggering a robust regenerative process
that resulted in almost complete regeneration of wild-type
muscles by 2 weeks after injury (Figure 6A–D). When mice
deficient in Fn14 were injected with cardiotoxin, however,
regeneration appeared to be delayed compared with that seen
in wild-type muscles (Figure 6E–H). For example, large
numbers of newly formed muscle fibers with their ‘signature’
centrally located nuclei appeared in TA muscles of wild-type
mice at 5 and 7 days following cardiotoxin injection, whereas
such regenerated myofibers were rare in Fn14/ mice at
TWEAK/Fn14 pathway and muscle regeneration
M Girgenrath et al
&2006 European Molecular Biology Organization The EMBO Journal VOL 25 | NO 24 | 2006 5831
AC
E F K
ID
L
G
J
Wild type
Day 3
Fn14–/– Wild type Fn14–/–
B H
Day 5
TWEAK in situ
No inj.
Fn14 in situ 
0
500
1000
1500
2000
Days after
injury:
0 3 50 3 50 3 5
Genotype: Wild type Fn14–/– Wild type
Si
gn
al
 in
te
ns
ity
(g
ra
ins
/m
m2
)
TWEAK mRNA
M
0
0.01
0.02
0.03
0.04
0.05
1
N
TW
EA
K
 m
R
N
A
 le
ve
l
(n
or
ma
liz
ed
)
Macrophages (Mac-1+)
Myoblasts
Flow-through cells 
Wild type Fn14–/–
Fn14 mRNA
* *
* *
0.00000
0.00005
0.00010
0.00015
0.00020
0.000000
0.000005
0.000010
0.000015
0.000020
0.000025
0.000030
0.000035
0.000
0.025
0.050
0.075
0.0000
0.0005
0.0010
0.0015
0.0020
0.000
0.001
0.002
0.003
0.004
0.005
0.006
0.007
O
EDA
XEDAR
TNF
Wild type
TNFR1
TNFR2
No CTX Day 3
No CTX Day 3
Fn14–/–
Figure 5 TWEAK and Fn14 mRNAs increased upon injury, but increased TWEAK persists longer in Fn14/ than in wild-type muscles and is
produced by macrophages. (A–L) In situ hybridzation of TWEAK (A–F) and Fn14 (G–L) mRNAs in control (no inj) and cardiotoxin-treated
wild-type and Fn14/ muscles at 3 or 5 days post injection as indicated. Scale bar in (A) represents 100mm. (M) At day 3 after cardiotoxin
treatment, quantification of grain density showed that TWEAK mRNA was significantly (Po0.01, n¼ 4) increased several-fold in both wild-
type (gray bars) and Fn14/ (blue bars) muscles. At day 5, in constrast, TWEAK persisted at a high level in Fn14/ muscles, but returned to
near the initial level in wild-type muscles. Fn14 mRNA was also increased by injury at days 3 and 5 in wild-type muscles (green bars, right
panel). Error bars¼ s.d. No Fn14 signal above background was found in Fn14/ muscles (not shown). (N) Macrophages are the major source
of TWEAK expression in regenerating muscles. At 3 days after cardiotoxin, TA muscles (n¼ 3) were dissociated into single-cell suspensions and
three cell preparations were made: (i) cells positive for the macrophage marker Mac-1þ were purified using Mac-1 magnetic beads
(macrophages, blue bars); (ii) myogenic cells were purified on a Percoll gradient (myoblasts, red bars); and (iii) Mac-1-negative cells,
which were cells that did not bind to the Mac-1 beads (flow-through, green bars). RNA was isolated from each cell fraction and quantitative
PCR was used to measure the amount of TWEAK mRNA in each cell type using an equal amount of input RNA and normalized versus the
amount of GAPDH mRNA. TWEAK mRNA expression was significantly higher (*Po0.05, n¼ 3) in macrophages than in myoblasts or flow-
through cells. Error bars¼ s.d. (O) mRNA levels of TNF/TNFRs and EDA/XEDAR with and without cardiotoxin in wild-type and Fn14/ mice.
At 3 days after cardiotoxin (CTX), total RNA was isolated from TA muscles (n¼ 3) and quantitative PCR was used to measure the mRNA levels
for TNF, TNFR1, TNFR2, EDA and XEDAR. Statistical significance was not achieved between wild-type and Fn14-deficient mice.
TWEAK/Fn14 pathway and muscle regeneration
M Girgenrath et al
The EMBO Journal VOL 25 | NO 24 | 2006 &2006 European Molecular Biology Organization5832
these times (Figure 6B, C, F and G). By day 14, the regene-
rative process appeared to be nearly complete in wild-type
mice as shown by the clearance of inflammation and the
replacement of damaged myofibers by the newly formed
central nucleate fibers. In Fn14/ mice, however, signs of
residual muscle damage remained along with regenerated
fibers, and some inflammatory cells also persisted (Figure 6D
and H).
To further analyze the delayed regeneration in Fn14/
compared with wild-type muscles, we quantified the number
of central nucleate myofibers and examined expression of the
embryonic isoform of myosin heavy chain (eMyHC) at different
stages of regeneration. Myofibers in adult animals that have
centrally located nuclei or that express eMyHC are known to be
in the process of regeneration (e.g., DiMario et al, 1991; Pavlath
et al, 2003). Confirming that regeneration was delayed in the
Fn14/ muscles, central nucleate myofibers were significantly
less abundant in regenerating Fn14/ than in regenerating
wild-type muscles at both 5 and 7 days after injury (Figure
6I–K). At 14 days after injury, in contrast, the Fn14/ and
wild-type muscles had similar numbers of central nucleate
fibers. Furthermore, fibers that expressd eMyHC were less
abundant in Fn14/ muscles than in wild-type muscles at
4 days after injury (Figure 6L and M) and similar results
were seen at 5 and 7 days after injury (not shown).
With the interplay between inflammation and tissue
regeneration in mind, we explored the inflammatory res-
ponse following cardiotoxin in wild-type and Fn14/ mice.
Massive infiltration of inflammatory cells, mainly macro-
phages and neutrophils, is an early hallmark event of cardi-
otoxin-induced muscle regeneration which peaks around
3 days after injection (Figure 7A). In Fn14/ mice injected
with cardiotoxin, H&E staining revealed not only a signifi-
cantly reduced presence of such infiltrates at day 3, but also
a 2-day delay of peak infiltration in Fn14/ muscles to day
5 (Figure 6E and F). This observation was consistent with
our in situ analysis, which showed that TWEAK mRNA
(likely produced by infiltrating inflammatory cells) persisted
at 5 days post injury in Fn14/ but not in wild-type, mice
(Figure 5E, F and M).
To additionally assess, both qualitatively and quantita-
tively, the altered inflammatory response seen in Fn14/
mice, we dissociated TA muscles using pronase digestion at
different time points following cardiotoxin injection, and we
carried out FACS analyses to identify inflammatory cells in
the resulting single-cell suspensions. FACS analyses showed
that very few inflammatory cells were present in uninjured
TA muscles in either wild-type or Fn14/ mice, as assessed
by double staining with Mac-1 and Gr-1 (Figure 7A), which
are markers for myeloid lineage inflammatory cells including
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monocytes and neutrophils (Lagasse and Weissman, 1996).
Following cardiotoxin injection, wild-type muscles showed
a very large increase of Mac-1þ/Gr-1þ infiltrating cells with
the percentage increasing from roughly 1% of the cells in
uninjured muscles to 28% of the cells at day 3 after injury.
Infiltrating cells also increased in injured Fn14/ TA mus-
cles, but the increase was smaller than in wild-type muscles,
as Mac-1þ/Gr-1þ cells accounted for less than 20% of the
total isolated cells on day 3 from injured Fn14/ TA muscles.
The difference between inflammation in wild-type and
Fn14/ muscles was even more pronounced in the Mac-
1hi/Gr-1þ subpopulation (marking monocytes/macrophages
in a more activated state; Lagasse and Weissman, 1996),
where the percentage in wild-type TA was more than double
that in the Fn14/ TA at 3 days after injury (14.6 versus
6.5%). We further confirmed our observation histologically
by staining with the more specific monocyte/macrophage
marker F4/80. On day 3, extensive F4/80þ infiltrates were
located around the damaged muscle fibers in the wild-type
muscles (Figure 7B and D). In Fn14/ mice, however, the
number of F4/80þ infiltrating cells was much less than in
wild-type mice at day 3 (Figure 7C and E).
Because chemokines play a critical role in regulating the
recruitment of inflammatory cells and TWEAK can potently
induce chemokine production from C2C12 cells based on our
profiling study (Figure 3), we conducted quantitative RT–PCR
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experiments to determine the temporal expression of several
key chemokines following cardiotoxin injection in both
wild-type and Fn14 knockout mice. As shown in Figure 7F,
RANTES does not seem to play a key role in the immediate
early phase following cardiotoxin injection, as no increase in
its expression level was seen after day 1. However, the levels
of MCP-1 were increased comparably in both wild-type and
Fn14/ mice, whereas the expression of MCP-3 was signifi-
cantly lower in the absence of Fn14 at day 1 post cardiotoxin-
induced injury, suggesting that MCP-3 might be a key
mediator for the recruitment of inflammatory infiltrates in
this model. Not surprisingly, the levels of MCP-3, MCP-1 and
RANTES all trended higher in Fn14/ mice at day 3 com-
pared with wild-type mice, likely contributing to the delayed
inflammation in these mice.
Discussion
In this study, we identified mesenchymal precursor cells as a
novel target cell type for the inflammatory cytokine TWEAK,
showing Fn14 expression on mesenchymal stem cells and all
progenitor cells of this lineage. Using muscle myoblasts as an
experimental system, we demonstrated that TWEAK stimu-
lated proliferation of primary myoblasts and that Fn14-
deficient myoblasts exhibited reduced proliferative capacity
in vitro. In addition, TWEAK altered the differentiating capa-
city of both C2C12 and primary skeletal myoblast cells.
Furthermore, our in vivo studies demonstrated upregulation
of TWEAK and Fn14 expression within injured muscle
tissue and delayed muscle regeneration in Fn14-deficient
animals. Thus, the TWEAK/Fn14 pathway is an important
modulator of the proliferative and differentiating potentials of
skeletal muscle progenitor cells. In addition, we also defined
TWEAK/Fn14 as a new biological pathway that regulates the
properties of mesenchymal stem cells, herein showing
TWEAK-induced NF-kB activation, as well as expression of
pro-survival, pro-proliferative and cell adhesion genes.
The past few years have seen tremendous progress with
respect to understanding the potential of mesenchymal
progenitors in tissue repair and regeneration. However,
our relatively poor understanding of factors governing their
survival, homing, proliferation and differentiation presents
a major challenge for a successful transition into clinical
applications. In addition to TWEAK’s proliferative effect on
muscle myoblasts, we have also observed that TWEAK could
potently inhibit the terminal differentiation of human osteo-
blast precursors, as well as adipogenesis and chondrogenesis
of human mesenchymal stem cells in culture (B Browning
and TS Zheng, unpublished results). Moreover, our profiling
study indicated that TWEAK could induce the expression of
antiapoptotic as well as cell adhesion molecules in mesench-
ymal stem cells, thus potentially affecting their homing and
survival capacity in vivo. The ability of the TWEAK/Fn14
pathway to broadly regulate these critical properties of
mesenchymal precursor cells might therefore present an
opportunity of ‘TWEAKing’ existing approaches for cell-
based regenerative therapies, particularly in skeletal, cardiac
and joint injury settings (Barry, 2003). This notion is consis-
tent with our recent finding that TWEAK also potentiates
the proliferation of liver progenitor cells (Fausto, 2005;
Jakubowski et al, 2005), suggesting a fundamental involve-
ment of this pathway in modulating progenitor cell behavior.
We found that activation of the TWEAK/Fn14 pathway
inhibited differentiation and increased proliferation of both
the immortalized C2C12 muscle cell line and primary myo-
genic cells. Our finding is consistent with previous demon-
stration that activation of the NF-kB pathway could drive cell
proliferation and inhibit C2C12 differentiation through reg-
ulation of cyclin D1 (Guttridge et al, 1999). While our paper
was under initial review, Dogra et al (2006) published their
study, which also demonstrated that C2C12 differentiation is
inhibited by TWEAK, and that TWEAK activates the NF-kB
pathway and decreases the amount of MyoD. The results of
Dogra et al are consistent with ours, and we additionally
demonstrated the effect of TWEAK on different types of
mesenchymal progenitor cells, identified differences between
the responses of C2C12 and primary muscle cells to
TWEAK, prepared Fn14/ mice to inactivate the TWEAK
pathway and identified a significant role for the TWEAK/
Fn14 pathway in regulating skeletal muscle regeneration after
injury in vivo.
Identification of the TWEAK/Fn14 pathway as a regulator
of muscle myoblast cell proliferation and differentiation
following muscle injury in vivo is significant. Previously, a
number of soluble factors, such as members of the FGF
family, PDGF, TGFb, myostatin, IGF, HGF and TNF, have
been implicated in the proliferation and differentiation of
muscle precursor cells based on in vitro studies. Studies using
knockout mice, however, have not always provided unequi-
vocal support of the in vitro observations, possibly owing to
the presence of redundant mechanisms in vivo. For example,
as a well-documented cachetic factor on muscle fibers, TNF
has been reported to inhibit differentiation, promote proli-
feration, and induce apoptosis of myoblast cells in vitro
(Stewart et al, 2004); however, muscle regeneration occurs
normally in TNF/ mice (Collins and Grounds, 2001), a
result that is in marked contrast to the delayed regeneration
in mice lacking the TWEAK receptor Fn14 (this study). A
further complication comes from the fact that most of these
factors also exert potent effects on many other cell types
including mature muscle fibers, making interpretation of
their direct effect on muscle precursor cells from in vivo
studies less straightforward. Based on our in situ data,
Fn14 expression in quiescent muscle tissue seems to be
very low, but drastically increases following cardiotoxin-
induced muscle damage. Coupled with the observation that
no apparent developmental defect in the muscle tissues was
seen in either the Fn14 knockout mice or TWEAK over-
expressing transgenic mice (LC Burkly, unpublished results),
it appears that TWEAK/Fn14 is a unique pathway that
becomes specifically engaged in muscle myoblast prolifera-
tion only during injury settings. Supporting this hypothesis,
dramatic upregulation of Fn14 mRNA was also observed in
the denervated muscle tissues of the mutant SOD transgenic
model of ALS (J Lincecum and S Perrin, unpublished results).
Although delayed by several days, regeneration in Fn14/
mice following cardiotoxin injury eventually became as com-
plete as in wild-type muscles, showing that the TWEAK/Fn14
pathway is one of the multiple pathways that likely contri-
bute to muscle regeneration. In many biological systems,
wholly or partially redundant mechanisms are commonly
found. One example is the transcriptional regulation of
myogenesis by MyoD and Myf-5 during development
(Rudnicki et al, 1993). Although we clearly demonstrated
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that TWEAK and TNF could inhibit C2C12 myogenesis
independent of each other in vitro, it is still tempting to
speculate that TWEAK and TNF could synergize with
and potentially compensate for each other in vivo, given
that they both are potent activators of the NF-kB pathway.
In fact, it has been previously shown that TWEAK and TNF
could synergistically induce the production of chemokines
and cytokines in dermal fibroblasts (Chicheportiche et al,
2002). The intriguing possibility of such synergism between
TNF and TWEAK in regulating muscle regeneration and other
biological systems in vivo remains to be investigated. In
addition, although not statistically significant, there seems
to be some level of compensatory activation of the TNF/
TNFR and EDA/XEDAR pathways in Fn14 knockout mice
following cardiotoxin injury according to our quantitative
RT–PCR analysis, a finding that reinforces the complex
and often redundant nature of many biological responses.
However, our study clearly shows that TWEAK and TNF are
two independent ligand/receptor pathways important for the
regulation of biological properties of mesenchymal and
muscle cells; our study is therefore consistent with the
results from a complete survey of binding between TNF
family receptors and ligands, which showed that TWEAK
bound only to Fn14 and TNF bound only to TNFR1 and
TNFR2 (Bossen et al, 2006).
The mechanism by which Fn14 deficiency resulted in
delayed muscle regeneration following cardiotoxin injection
is likely two-fold. First, based on our in vitro observations
with the C2C12 line and isolated primary muscle myoblasts,
it is likely that, similar to the reduced proliferative capacity
seen with isolated Fn14/ myoblasts in culture, the expan-
sion of myoblasts triggered by cardiotoxin was less than
optimal in Fn14/ mice, resulting in delayed muscle regene-
ration. Although we did observe delayed BrdU incorporation
in Fn14/ mice compared with wild-type mice (data not
shown) using a pulsing protocol that is reported to label only
myoblasts (Yan et al, 2003), we were unable to demonstrate
experimentally that those BrdU-labeled cells were all
myoblasts. As a result, we cannot conclude with absolute
certainty that myoblast proliferation was directly affected
in cardiotoxin-injured Fn14/ mice. The second possible
mechanism for delayed muscle regeneration could be due
to the reduced inflammatory response in Fn14/ mice, as
inflammation could certainly contribute positively to efficient
muscle regeneration by a number of means, including
removal of debris from damaged fibers and secretion of
soluble factors that promote muscle regeneration.
Although seemingly independent events, the proliferation/
activation of myoblasts and inflammation during muscle
regeneration might actually be tightly coupled, as suggested
by the compelling evidence for active crosstalks between
muscle precursor cells and inflammatory infiltrates in a
recent study (Chazaud et al, 2003). We believe that the
TWEAK/Fn14 pathway could very well be a mediator of
such cellular interactions and one can envision a scenario
of how the TWEAK/Fn14 pathway may function as a positive
regulator of muscle precursor cell properties during injury-
triggered muscle regeneration (Figure 8). Following cardio-
toxin injection, necrotic muscle fibers can release a number
of soluble factors, including chemokines that will recruit
neutrophils and macrophages (Tsivitse et al, 2005), as well
as FGFs (D’Amore, 1990), which would induce Fn14 expres-
sion on muscle precursor cells. As a result, TWEAK produced
by the early inflammatory infiltrates would engage Fn14-
expressing muscle precursor cells, resulting in not only
their proliferation, but also enhanced production of chemo-
kines important for recruitment of additional inflammatory
cells that are beneficial to the repair response, thus creating
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Figure 8 A working model for regulation of muscle regeneration by the TWEAK/Fn14 pathway. Cardiotoxin-induced injury triggers release of
soluble factors that recruit early inflammatory cells and induce Fn14 expression on muscle precursor cells. Secreted by infiltrating
inflammatory cells, TWEAK engages Fn14 and promotes the proliferation and activation of myoblasts, which can in turn contribute to a
robust inflammatory response by producing additional chemotactant. The TWEAK/Fn14 pathway therefore positively contributes to muscle
regeneration by promoting cellular crosstalk between inflammatory cells and muscle precursor cells.
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a positive feedback loop promoting muscle regeneration. This
notion is consistent with our C2C12 profiling result demon-
strating that TWEAK induced drastic upregulation of several
chemokines critical for macrophage recruitment including
MCP-1, MCP-3, RANTES and MIP-1 (Figure 3A), whose
expressions are significantly induced following cardiotoxin-
induced muscle injury (Hirata et al, 2003). In fact, our real-
time PCR analysis confirmed that the initial MCP-3 expres-
sion following cardiotoxin injury was much reduced in the
absence of Fn14, and suggests that MCP-3-mediated chemo-
taxis is an important downstream trigger for the TWEAK/
Fn14-induced inflammatory response amplification loop.
It has traditionally been thought that inflammatory res-
ponses following tissue injury are critical for the clearance of
damaged tissue debris and removal of necrotic/apoptotic
cells. A number of more recent studies, however, provided
growing evidence, suggesting that inflammation can also
influence tissue repair by directly acting on the regenerating
cell pool (Mutsaers et al, 2002; Arnett et al, 2003; Monje et al,
2003). In our current study, we demonstrated TWEAK’s
ability to drive the expansion of muscle myoblasts in vitro
and apparently in vivo in response to injury, presenting a
concrete example of how a cytokine derived from inflamma-
tory cells can participate in tissue repair and regeneration.
Given the broad expression of Fn14 on progenitor cells of the
mesenchymal lineage and its rapid upregulation in many
injury settings, we propose that the physiological function
of the TWEAK/Fn14 pathway is to participate in acute phase
tissue repair in multiple biological systems by promoting
progenitor cell proliferation. On the other hand, we have
also observed that TWEAK potently inhibited the terminal
differentiation of muscle myoblasts, as well as other mesen-
chymal progenitor cells. One could therefore envision that
under pathological conditions where inflammatory responses
persist, prolonged presence of TWEAK could potentially
block the differentiation of progenitor cells and impede
efficient tissue repair. The complex physiological and patho-
logical consequences of TWEAK activity suggest that mani-
pulation of the TWEAK system may present therapeutic
opportunities for cell-based regenerative therapy and in
various inflammatory diseases such as arthritis and athero-
sclerosis, where extensive tissue remodeling and regene-
ration occur.
Materials and methods
Proteins and antibodies
The construct for Fc-TWEAK was generated by replacing the Baff
portion of a previously described Fc-Baff construct with a cDNA
fragment encoding soluble TWEAK. A stable 293T cell line
expressing the construct was then generated for protein production.
The hamster anti-TWEAK antibody ABG.11 and anti-human Fn14
antibody ITEM-4 were generated as previously described (Jaku-
bowski et al, 2002; Nakayama et al, 2003). The blocking anti-Fn14
antibody P2D3 was generated by immunizing Fn14 knockout mice
with Fn14-transfected cells. The following antibodies were pur-
chased from the indicated sources: anti-mouse TNF G281-2626, PE-
anti-human CD56, FITC-anti-mouse Mac-1 and PE-anti-mouse Gr-1
(BD Biosciences), anti-myogenin F5D (Santa Cruz Biotechnology).
Cell culture
C2C12 cells (ATCC) were seeded at 2105 cells/well in six-well
plates in growth medium (GM; DMEM supplemented with 15%
FBS). The following day, cells were washed with PBS once and
switched to low-serum differentiation medium (DM: DMEM
supplemented with 2% horse serum). Primary muscle satellite
cells were isolated from limb muscles of 6- to 8-week-old Fn14/
mice and wild-type control mice (n¼ 4, for each group) as
described (Dominov et al, 1998, 2001; Girgenrath et al, 2005).
See Supplementary data for additional details. Primary myoblasts
were induced to differentiate by replacing GM with (DM that
consisted of DMEM without chicken embryo extract and with only
2% serum. Human primary cells were all purchased from Cambrex
(Walkersville, MD) and cultured according to the supplier’s
protocol.
Cardiotoxin injection
Cardiotoxin injection was performed as before (Yan et al, 2003).
Briefly, 50ml of 10 mM cardiotoxin (Sigma) was injected into the TA
muscles of the right legs of wild-type or Fn14-deficient mice of
129/sv background, whereas the left legs were used as uninjected
control. At the indicated time points, TA muscles were harvested
and fixed in 4% paraformaldehyde. For BrdU incorporation, mice
were injected intraperitoneally with 1 mg of BrdU 6 hours before
harvesting the muscles.
Profiling analysis
For transcription profiling of TWEAK’s effect on C2C12 cells,
1.2106 C2C12 cells were seeded in 100-mm cell culture dishes in
GM overnight before being switched to differentiation medium.
Total RNA from C2C12 cells cultured in GM and DM at different
time points was extracted using TriZol reagent (Invitrogen) and
further purified by RNAeasy (Qiagen). Duplicate samples for each
sample point were subjected to profiling using the Affymetrix
mouse chip MG-U74A according to the protocol recommended by
the manufacturer. For profiling of TWEAK’s effect on MSCs, 2106
cells were cultured in 100-mm cell culture dishes in regular DMEM
culture medium containing different serum concentrations (10, 2 or
0.2%). After overnight culture, TWEAK (100 ng/ml) or heat-
inactivated TWEAK (100ng/ml) were added in triplicate plates for
each treatment condition and cells were harvested 18 h later for
profiling using the Affymetrix human chip U133.
FACS
Fc-TWEAK binding to and Fn14 surface expression on primary cells
were analyzed by FACS staining according to the standard protocol.
Briefly, cells were harvested by incubating in 5 mM EDTA/PBS
solution at 371C until the cells detached. Cells were suspended in
FACS buffer (PBS with 1% FBS) and stained with either 100 ng/ml
of Fc-TWEAK or 1 mg/ml of ITEM-4 for 45 min, followed by PE-
conjugated goat anti-human or mouse Fc secondary antibodies.
Samples were read on a FACS Calibur and analyzed using FlowJo.
For FACS of muscle dissociates, TA muscles were dissected, fat and
connective tissues were removed, and minced muscles were
incubated in 0.2 mg/ml Pronase solution (Roche Diagnostics) at
371C for 1 h. After terminating digestion by washing with DMEM,
the dissociates were recovered by sequentially filtering through
100mm and 40 mm cell strainers (BD Labware) and used for staining
with anti-Mac-1 and anti-Gr-1 antibodies.
NF-jB activation assay
NF-kB activation was measured (n¼ 3) using the TransAM NF-kB
p65 assay system (Active Motif) according to the manufacturer’s
protocol.
For details on quantitative PCR, generation of Fn14/ mice,
in situ hybridization and histological analyses, see Supplementary
data.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
Acknowledgements
We sincerely thank L Evangelisti and S Shulga-Morskaya for em-
bryonic stem cell culture and injection; M Wang and J Lincecum for
in situ analysis; T Crowell and H Gardner for histological analysis;
D Gong for protein purification; D McCrann, J Shearston, S Perrin
and S Szak for gene profiling analysis. This work was supported in
part by NIH Grant HL39727 (JAW) and Grants AR49496, ES11384
and HL64641 (JBM).
TWEAK/Fn14 pathway and muscle regeneration
M Girgenrath et al
&2006 European Molecular Biology Organization The EMBO Journal VOL 25 | NO 24 | 2006 5837
References
Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP
(2001) TNF alpha promotes proliferation of oligodendrocyte
progenitors and remyelination. Nat Neurosci 4: 1116–1122
Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP (2003)
Functional genomic analysis of remyelination reveals importance
of inflammation in oligodendrocyte regeneration. J Neurosci 23:
9824–9832
Barry FP (2003) Biology and clinical applications of mesenchymal
stem cells. Birth Defects Res Part C Embryo Today 69: 250–256
Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S,
Ambrose C, Tschopp J, Schneider P (2006) Interactions of tumor
necrosis factor (TNF) and TNF receptor family members in the
mouse and human. J Biol Chem 281: 13964–13971
Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA (2003)
The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-
associated factors 1, 2, 3 and 5 and mediates nuclear factor-
kappaB activation. Biochem J 371: 395–403
Chazaud B, Sonnet C, Lafuste P, Bassez G, Rimaniol AC, Poron F,
Authier FJ, Dreyfus PA, Gherardi RK (2003) Satellite cells attract
monocytes and use macrophages as a support to escape apoptosis
and enhance muscle growth. J Cell Biol 163: 1133–1143
Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C,
Garcia I, Browning JL (1997) TWEAK, a new secreted ligand in
the tumor necrosis factor family that weakly induces apoptosis.
J Biol Chem 272: 32401–32410
Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J,
Benjamin CB, Ambrose C, Dayer JM (2002) Proinflammatory
activity of TWEAK on human dermal fibroblasts and synovio-
cytes: blocking and enhancing effects of anti-TWEAK monoclonal
antibodies. Arthritis Res 4: 126–133
Collins RA, Grounds MD (2001) The role of tumor necrosis factor-
alpha (TNF-alpha) in skeletal muscle regeneration. Studies
in TNF-alpha(/) and TNF-alpha(/)/LT-alpha(/) mice.
J Histochem Cytochem 49: 989–1001
Couteaux R, Mira JC, d’Albis A (1988) Regeneration of muscles after
cardiotoxin injury. I. cytological aspects. Biol Cell 62: 171–182
D’Amore PA (1990) Modes of FGF release in vivo and in vitro.
Cancer Metast Rev 9: 227–238
DiMario JX, Uzman A, Strohman RC (1991) Fiber regeneration is not
persistent in dystrophic (MDX) mouse skeletal muscle. Dev Biol
148: 314–321
Dogra C, Changotra H, Mohan S, Kumar A (2006) Tumor necrosis
factor-like weak inducer of apoptosis inhibits skeletal myogenesis
through sustained activation of nuclear factor-kappaB and degra-
dation of MyoD protein. J Biol Chem 281: 10327–10336
Dominov JA, Dunn JJ, Miller JB (1998) Bcl-2 expression identifies
an early stage of myogenesis and promotes clonal expansion of
muscle cells. J Cell Biol 142: 537–544
Dominov JA, Houlihan-Kawamoto CA, Swap CJ, Miller JB (2001)
Pro- and anti-apoptotic members of the Bcl-2 family in skeletal
muscle: a distinct role for Bcl-2 in later stages of myogenesis. Dev
Dyn 220: 18–26
Duffield JS (2003) The inflammatory macrophage: a story of Jekyll
and Hyde. Clin Sci (London) 104: 27–38
Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O (2003)
Inflammation is detrimental for neurogenesis in adult brain.
Proc Natl Acad Sci USA 100: 13632–13637
Fausto N (2005) Tweaking liver progenitor cells. Nat Med 11:
1053–1054
Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR,
Peifley KA, Winkles JA (2000) The Fn14 immediate-early re-
sponse gene is induced during liver regeneration and highly
expressed in both human and murine hepatocellular carcinomas.
Am J Pathol 156: 1253–1261
Girgenrath M, Kostek CA, Miller JB (2005) Diseased muscles that
lack dystrophin or laminin-alpha2 have altered compositions and
proliferation of mononuclear cell populations. BMC Neurol 5: 7
Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS
(1999) NF-kappaB controls cell growth and differentiation
through transcriptional regulation of cyclin D1. Mol Cell Biol
19: 5785–5799
Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin Jr AS
(2000) NF-kappaB-induced loss of MyoD messenger RNA:
possible role in muscle decay and cachexia. Science 289:
2363–2366
Hawke TJ, Garry DJ (2001) Myogenic satellite cells: physiology to
molecular biology. J Appl Physiol 91: 534–551
Hirata A, Masuda S, Tamura T, Kai K, Ojima K, Fukase A, Motoyoshi
K, Kamakura K, Miyagoe-Suzuki Y, Takeda S (2003) Expression
profiling of cytokines and related genes in regenerating skeletal
muscle after cardiotoxin injection: a role for osteopontin. Am J
Pathol 163: 203–215
Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng
TS, Browning B, Michaelson JS, Baestcher M, Wang B, Bissell
DM, Burkly LC (2005) TWEAK induces liver progenitor cell
proliferation. J Clin Invest 115: 2330–2340
Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS,
Benjamin CD, Hsu YM, Ambrose C, Zheng TS, Burkly LC
(2002) Dual role for TWEAK in angiogenic regulation. J Cell Sci
115: 267–274
Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ (2001)
Macrophage depletion impairs oligodendrocyte remyelina-
tion following lysolecithin-induced demyelination. Glia 35:
204–212
Lagasse E, Weissman IL (1996) Flow cytometric identification of
murine neutrophils and monocytes. J Immunol Methods 197:
139–150
Lescaudron L, Peltekian E, Fontaine-Perus J, Paulin D, Zampieri M,
Garcia L, Parrish E (1999) Blood borne macrophages are essential
for the triggering of muscle regeneration following muscle trans-
plant. Neuromuscul Disord 9: 72–80
Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF
receptor superfamilies: integrating mammalian biology. Cell 104:
487–501
Luk HW, Noble LJ, Werb Z (2003) Macrophages contribute to the
maintenance of stable regenerating neurites following peripheral
nerve injury. J Neurosci Res 73: 644–658
Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR (1999)
TWEAK induces angiogenesis and proliferation of endothelial
cells. J Biol Chem 274: 8455–8459
Merly F, Lescaudron L, Rouaud T, Crossin F, Gardahaut MF (1999)
Macrophages enhance muscle satellite cell proliferation and delay
their differentiation. Muscle Nerve 22: 724–732
Miller SC, Ito H, Blau HM, Torti FM (1988) Tumor necrosis
factor inhibits human myogenesis in vitro. Mol Cell Biol 8:
2295–2301
Monje ML, Toda H, Palmer TD (2003) Inflammatory blockade
restores adult hippocampal neurogenesis. Science 302: 1760–1765
Morgan JE, Partridge TA (2003) Muscle satellite cells. Int J Biochem
Cell Biol 35: 1151–1156
Mutsaers SE, Whitaker D, Papadimitriou JM (2002) Stimulation of
mesothelial cell proliferation by exudate macrophages enhances
serosal wound healing in a murine model. Am J Pathol 160:
681–692
Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E,
Okumura K, Yagita H (2003) Fibroblast growth factor-inducible
14 mediates multiple pathways of TWEAK-induced cell death.
J Immunol 170: 341–348
Nathan C (2002) Points of control in inflammation. Nature 420:
846–852
Newton K, French DM, Yan M, Frantz GD, Dixit VM (2004)
Myodegeneration in EDA-A2 transgenic mice is prevented by
XEDAR deficiency. Mol Cell Biol 24: 1608–1613
Nowak JA, Malowitz J, Girgenrath M, Kostek CA, Kravetz AJ,
Dominov JA, Miller JB (2004) Immortalization of myogenic
cells does not require loss of p16INK4a, p19ARF, or p53 and is
accelerated by inactivation of Bax. BMC Cell Biol 5: 1–14
Pavlath GK, Dominov JA, Kegley KM, Miller JB (2003) Regeneration
of skeletal muscles with altered timing of expression of the
myogenic bHLH factor MRF4. Am J Pathol 162: 1685–1691
Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH,
Jaenisch R (1993) MyoD or Myf-5 is required for the formation of
skeletal muscle. Cell 75: 1351–1359
Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego
S, Chicheportiche Y, Dietrich PY (2000) TWEAK stimulation
of astrocytes and the proinflammatory consequences. Glia 32:
102–107
Stewart CE, Newcomb PV, Holly JM (2004) Multifaceted roles of
TNF-alpha in myoblast destruction: a multitude of signal trans-
duction pathways. J Cell Physiol 198: 237–247
TWEAK/Fn14 pathway and muscle regeneration
M Girgenrath et al
The EMBO Journal VOL 25 | NO 24 | 2006 &2006 European Molecular Biology Organization5838
Szalay K, Razga Z, Duda E (1997) TNF inhibits myogenesis and
downregulates the expression of myogenic regulatory factors
myoD and myogenin. Eur J Cell Biol 74: 391–398
Tsivitse SK, Mylona E, Peterson JM, Gunning WT, Pizza FX (2005)
Mechanical loading and injury induce human myotubes to release
neutrophil chemoattractants. Am J Physiol Cell Physiol 288: C721–729
Walsh K, Perlman H (1997) Cell cycle exit upon myogenic differ-
entiation. Curr Opin Genet Dev 7: 597–602
Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner
V, Liu H, Daniel TO, Smith CA, Fanslow WC (2001) A novel TNF
receptor family member binds TWEAK and is implicated in
angiogenesis. Immunity 15: 837–846
Yan Z, Choi S, Liu X, Zhang M, Schageman JJ, Lee SY, Hart R, Lin L,
Thurmond FA, Williams RS (2003) Highly coordinated gene
regulation in mouse skeletal muscle regeneration. J Biol Chem
278: 8826–8836
TWEAK/Fn14 pathway and muscle regeneration
M Girgenrath et al
&2006 European Molecular Biology Organization The EMBO Journal VOL 25 | NO 24 | 2006 5839
